<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093259</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-101</org_study_id>
    <nct_id>NCT03093259</nct_id>
  </id_info>
  <brief_title>ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis</brief_title>
  <official_title>Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming&#xD;
      at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in&#xD;
      subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant&#xD;
      to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month&#xD;
      follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming&#xD;
      at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in&#xD;
      subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant&#xD;
      to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month&#xD;
      follow-up period.&#xD;
&#xD;
      Eligible subjects will be randomized according to a 2/1 ratio in two different groups of&#xD;
      treatment. Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind Treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidences of treatment-emergent adverse events</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>Number of incidences of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-22 expression levels</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>Change from baseline in IL-22 expression levels (transcriptome) in serum and rectal/sigmoidal tissue compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA-124 levels</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>Change from baseline in microRNA-124 levels in whole blood (PAXgene®) compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mayo Score</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission according to the Total Mayo Score</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>Proportion of subjects receiving ABX464 with clinical remission according to the Total Mayo Score compared to placebo. Remission exclude friability and is based on total Mayo score ≤ 2 with no individual sub-score &gt; 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>ABX464 Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 50 mg of ABX464 orally once daily for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABX464 matching placebo Treatment Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464</intervention_name>
    <description>ABX464 is a new Anti-inflammatory drug</description>
    <arm_group_label>ABX464 Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo matching with ABX464</description>
    <arm_group_label>ABX464 matching placebo Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderate to severe active UC confirmed by endoscopy and histology at&#xD;
             least 12 weeks prior to screening visit. Moderate to severe active UC defined by Mayo&#xD;
             Clinic Score (MCS) of 6 to 12 inclusive (on a scale of 0-12). Moderate to severe&#xD;
             active UC should be confirmed at screening visit with a centrally read MCS endoscopy&#xD;
             score of at least 2 (on a scale of 0-3);&#xD;
&#xD;
          -  Subjects receiving oral corticosteroids must have been on a stable dose of prednisone&#xD;
             or prednisone equivalent ≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or&#xD;
             on budesonide MMX (≤9mg/day), for ≥2 weeks before first dosing (i.e. baseline);&#xD;
&#xD;
          -  Topical corticosteroids and topical 5-aminosalicylic acid preparations must have been&#xD;
             withdrawn ≥2 weeks before first dosing (i.e. baseline);&#xD;
&#xD;
          -  Subjects who are on oral 5-aminosalicylic acid must have been on a stable dose ≥4&#xD;
             weeks before first dosing (i.e. baseline);&#xD;
&#xD;
          -  Subjects who are receiving immunosuppressants in the form of azathioprine,&#xD;
             6-mercaptopurine, or methotrexate needed to be on a stable dose for 4 weeks before&#xD;
             first dosing (i.e. baseline). Subjects taking methotrexate also are advised to take&#xD;
             folic acid 1 mg/day (or equivalent) supplementation if there is no contraindication;&#xD;
&#xD;
          -  Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.],&#xD;
             Saccharomyces boulardii) must be on stable doses for 2 weeks before first dosing (i.e.&#xD;
             baseline);&#xD;
&#xD;
          -  Subjects on antidiarrheals (e.g., loperamide, diphenoxylate with atropine) must be on&#xD;
             stable doses for 2 weeks before first dosing (i.e. baseline);&#xD;
&#xD;
          -  Subjects who have previously received anti-tumor necrosis factor (TNF) therapy or&#xD;
             vedolizumab must have discontinued therapy ≥8 weeks before first dosing (i.e.&#xD;
             baseline);&#xD;
&#xD;
          -  Subjects previously treated with cyclosporine or tacrolimus must have discontinued&#xD;
             therapy ≥4 weeks before first dosing (i.e. baseline);&#xD;
&#xD;
          -  Subjects previously treated with tube feeding, defined formula diets, or parenteral&#xD;
             alimentation/nutrition must have discontinued treatment 3 weeks before first dosing&#xD;
             (i.e. baseline).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with Crohn's Disease (CD), indeterminate colitis (IC) or presence or history&#xD;
             of fistula with CD;&#xD;
&#xD;
          -  History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma;&#xD;
             history or is at imminent risk of colectomy;&#xD;
&#xD;
          -  History or current evidence of colonic dysplasia or adenomatous colonic polyps.&#xD;
             Subject with severe gastrointestinal complications; e.g., short bowel syndromes,&#xD;
             obstructing strictures, recent or planned bowel surgery, Ileostomy and/or colostomy,&#xD;
             recent bowel perforation;&#xD;
&#xD;
          -  Subject with significant and known active infections at screening such as Infected&#xD;
             abscess, positive for Clostridium difficile (stool antigen and toxin), CMV, TB and&#xD;
             recent infectious hospitalization;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul GINESTE</last_name>
    <role>Study Director</role>
    <affiliation>Abivax S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven - campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABX464</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 14, 2021</submitted>
    <returned>November 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

